4. Peptidic, Peptidomimetic, and HTS-Derived BACE Inhibitors

  1. Varghese John
  1. James P. Beck PhD and
  2. Dustin J. Mergott PhD

Published Online: 26 MAR 2010

DOI: 10.1002/9780470594087.ch4

BACE: Lead Target for Orchestrated Therapy of Alzheimer's Disease

BACE: Lead Target for Orchestrated Therapy of Alzheimer's Disease

How to Cite

Beck, J. P. and Mergott, D. J. (2010) Peptidic, Peptidomimetic, and HTS-Derived BACE Inhibitors, in BACE: Lead Target for Orchestrated Therapy of Alzheimer's Disease (ed V. John), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470594087.ch4

Editor Information

  1. Buck Institute for Age Research Novato, California, USA

Author Information

  1. Discovery Chemistry Research & Technology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA

Publication History

  1. Published Online: 26 MAR 2010
  2. Published Print: 11 FEB 2010

ISBN Information

Print ISBN: 9780470293423

Online ISBN: 9780470594087

SEARCH

Keywords:

  • peptidic, peptidomimetic and HTS-derived BACE inhibitors;
  • Oklahoma Medical Research Foundation (OMRF)/multiple collaborators;
  • Schering Plough Corporation and HEA BACE-1 inhibitors

Summary

This chapter contains sections titled:

  • Introduction

  • Elan/Pharmacia (Pfizer)

  • Oklahoma Medical Research Foundation (OMRF)/Multiple Collaborators

  • Eli Lilly

  • Merck

  • GlaxoSmithKline

  • Schering Plough

  • Bristol-Myers Squibb

  • Novartis

  • Amgen

  • Wyeth

  • Final Remarks

  • References